In summary, our combined SNP- and gene-based analyses revealed the association of two novel loci (rs3217869/CCND2 and rs12643184/PDGF-C), and three genes (BAD, PDGF-D and CCND2) in the RTK/ERK signaling pathway with aggressive prostate cancer. The gene discussed is CCND2; the disease is prostate carcinoma.